Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib as Second-line Treatment After Sunitinib in mRCC
NCT02324803Phase 2Unknown
- Sponsor
- Southern China Urology Cancer Consortium
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in metastatic renal cell carcinoma (mRCC), sponsored by Southern China Urology Cancer Consortium. Primary endpoint: Progression-Free Survival up to 30 months. Status: unknown.
02
Drugs
pazopanib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02324803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324803.